Lev Silberstein

Lev Silberstein, M.D., Ph.D., is an Associate Professor at Fred Hutchinson Cancer Center in the Translational Science and Therapeutics Division and Associate Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine. A physician-scientist, he specializes in bone marrow failure and myelodysplastic syndromes while leading the Silberstein Lab focused on hematopoietic stem cell biology.

His educational background includes:

• M.D. from Novosibirsk Medical Institute, Russia
• Ph.D. from University of Cambridge, UK
• Residency at The Royal London Hospital, UK
• Fellowships at University College Hospital, London and Harvard University

Research centers on microenvironmental regulation of hematopoietic stem cell quiescence and self-renewal. Current projects investigate Sema4A, Angiogenin, and novel niche regulators to develop therapies for bone marrow failure and post-transplant reconstitution. His work bridges basic discovery in stem cell niche biology with clinical translation.

Publication trends (2011-2018) emphasize single-cell analysis of the bone marrow niche, identifying extrinsic regulators like angiogenin and prostaglandin E2. Key themes include stem cell quiescence mechanisms, niche-derived therapeutic targets, and applications for myelodysplasia treatment, featured in Cell and Cell Stem Cell.

Awards include:

• Leukemia & Lymphoma Society Translational Research Program Grant
• Andy Hill Cancer Research Endowment Award

As PI, he mentors lab staff and collaborates with medical students/postdocs. Research is funded by competitive grants including the LLS award. National/international collaborations span Harvard, UC Merced, University of Munich, KU Leuven, and Weizmann Institute.

The Silberstein Lab operates within Fred Hutch's Stem Cell and Gene Therapy Program, maintaining active partnerships for interdisciplinary research in hematopoietic stem cell regulation and therapeutic development.